Preventing Crohn's Disease recurrence after resection with adalimumab: Role of drug and anti-drug antibody levels

被引：0

作者：

Wright, E. ^{[1
,2
]}

Kamm, M. ^{[1
,2
,3
]}

Selvaraj, F. ^{[4
]}

Princen, F. ^{[4
]}

De Cruz, P. ^{[1
,2
]}

Hamilton, A. ^{[1
,2
]}

Ritchie, K. ^{[1
,2
]}

Krejany, E. ^{[1
,2
]}

Gorelik, A. ^{[1
,2
]}

Liew, D. ^{[1
,2
]}

Prideaux, L. ^{[1
,2
]}

Lawrance, I. ^{[1
,2
]}

Andrews, J. ^{[1
,2
]}

Bampton, P. ^{[1
,2
]}

Jakobovits, S. ^{[1
,2
]}

Florin, T. ^{[1
,2
]}

Gibson, P. ^{[1
,2
]}

Debinski, H. ^{[1
,2
]}

Gearry, R. ^{[1
,2
]}

Macrae, F. ^{[1
,2
]}

Samuel, D. ^{[1
,2
]}

Kronborg, I. ^{[1
,2
]}

Radford-Smith, G. ^{[1
,2
]}

Selby, W. ^{[1
,2
]}

Johnston, M. ^{[1
,2
]}

Woods, R. ^{[1
,2
]}

Elliott, P. R. ^{[1
,2
]}

Bell, S. ^{[1
,2
]}

Brown, S. ^{[1
,2
]}

Connell, W. ^{[1
,2
]}

Desmond, P. ^{[1
,2
]}

Singh, S. ^{[4
]}

机构：

[1] St Vincents Hosp, Melbourne, Vic, Australia

[2] Univ Melbourne, Gastroenterol, Melbourne, Vic, Australia

[3] Univ London Imperial Coll Sci Technol & Med, Med, London, England

[4] Prometheus Labs, Dept Res & Dev, San Diego, CA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P585

引用

页码：S373 / S373

页数：1

共 50 条

[41] UTILITY OF MEASURING ADALIMUMAB DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN CLINICAL PRACTICE: A LARGE IBD REFERRAL CENTRE EXPERIENCE
Warner, B. D.
Johnston, E. L.
Digby-Bell, J. L.
Unsworth, N.
Anderson, S.
Sanderson, J. D.
Arkir, Z.
Irving, P. M.
GUT, 2015, 64 : A93 - A93
[42] DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB
Jyssum, I.
Gehin, J. E.
Kristianslund, E.
Sexton, J.
Worren, D.
Hu, Y.
Kvien, T. K.
Haavardsholm, E. A.
Bolstad, N.
Syversen, S. W.
Goll, G. L.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 362 - 363
[43] Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti-drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD)
Brown, Sara
Perinbasekar, Rajiv
Syed, Nauroz
Lonsako, Shumet
Cross, Raymond
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S406 - S406
[44] PROACTIVE MONITORING OF INFLIXIMAB (IFX) AND ADALIMUMAB (ADA) DRUG AND ANTI-DRUG ANTIBODY CONCENTRATION UTILIZING THE LABCORP ASSAY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
Perinbasekar, Rajiv A.
Brown, Sara A.
Syed, Nauroz
Lonsako, Shumet
Cross, Raymond K.
GASTROENTEROLOGY, 2017, 152 (05) : S392 - S392
[45] THE PRESENCE OF TOTAL ANTI-DRUG ANTIBODIES TO BIOLOGIC DRUGS DOES NOT ADVERSELY AFFECT LONG-TERM OUTCOMES IN CROHN'S DISEASE PATIENTS WITH ADEQUATE DRUGS LEVELS AND ABSENT FREE ANTI-DRUG ANTIBODIES
Samaan, M. A.
Unsworth, N.
Ward, M.
Warner, B.
Sanderson, J. D.
Arkir, Z.
Irving, P. M.
GUT, 2016, 65 : A255 - A256
[46] Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
Vallejos, Chelsea
Cooper, Jennifer
Pan, Ingrid
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 705 - 707
[47] NONBIOLOGIC DRUG USE BEFORE AND AFTER INITIATION OF USTEKINUMAB OR ADALIMUMAB FOR CROHN'S DISEASE PATIENTS
Obando, Camilo
Ding, Zhijie
Muser, Erik
Slaton, Terra
Kozma, Chris
GASTROENTEROLOGY, 2019, 156 (06) : S882 - S882
[48] Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease
Papamichael, Konstantinos
Dubinsky, Marla C.
Cheifetz, Adam S.
GASTROENTEROLOGY, 2023, 164 (01) : 164 - 165
[49] Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory
Keating, Paula Elizabeth
Hock, Barry D.
Chin, Paul K. L.
O'Donnell, John Liston
Barclay, Murray Lindsay
THERAPEUTIC DRUG MONITORING, 2024, 46 (05) : 619 - 626
[50] Drug choice in preventing postoperative Crohn's disease - Reply
McLeod, RS
GASTROENTEROLOGY, 1996, 110 (02) : 652 - 653

← 1 2 3 4 5 →